Article Figures & Data
Figures
Tables
Data Supplement
- Supplemental Data -
Supplemental Methods
Supplemental Fig. S1. Simulated and observed mouse M3258 PK profiles.
Supplemental Fig. S2. Observed and model-fitted tumor volumes in U266B1 xenograft tumor-bearing mice treated with M3258 (p.o.) administered at 1 mg/kg daily (orange line and circles), once every two days (blue line and triangles) or twice weekly (green line and diamonds) or with vehicle only (black line and squares).
Supplemental Fig. S3. Simulated and observed tumors volumes in for alternate M3258 dosing schedules.
Supplemental Fig. S4. Simulated and observed tumors volumes in M3258 dose range finding study.
Supplemental Fig. S5. Diagnostic plots for the tumor growth inhibition model.
Supplemental Fig. S6. Simulated and observed rat PD profile.
Supplemental Fig. S7. Simulated and observed mouse M3258 PD profiles.
Supplemental Fig. S8. Simulated and observed dog M3258 PD profiles.
Supplemental Fig. S9. Observed PD vs. PD predicted using the M3258 PK/PD models in mouse (A) and dog (B) black
dots, overlaid with the unity line (red line).
Supplemental Fig. S10. Correlation between tumor growth inhibition of U266B1 xenografts in mice and Cmax (A), Cmin (B) and weekly AUC (C) of M3258 plasma exposure estimated by non-compartmental analysis.
Supplemental Table S1. Prediction of M3258 human clearance using different methods.
Supplemental Table S2. Prediction of M3258 human volume of distribution using different methods.
Supplemental References.
- Supplemental Data -